Stralem & Co’s AbbVie ABBV Stock Holding History

Stralem & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$4.03M	Sell	41,055 -506	-1%	-$44.6K	2.57%	23
2020 Q1	$3.17M	Sell	41,561 -4,670	-10%	-$398K	2.35%	28
2019 Q4	$4.09M	Sell	46,231 -11,930	-21%	-$990K	2.29%	32
2019 Q3	$4.4M	Sell	58,161 -229	-0.4%	-$15.7K	2.54%	27
2019 Q2	$4.25M	Sell	58,390 -12,250	-17%	-$963K	2.31%	32
2019 Q1	$5.69M	Sell	70,640 -3,325	-4%	-$272K	2.61%	29
2018 Q4	$6.82M	Sell	73,965 -33,620	-31%	-$2.96M	3.25%	7
2018 Q3	$10.2M	Sell	107,585 -3,100	-3%	-$294K	3.02%	18
2018 Q2	$10.3M	Sell	110,685 -53,730	-33%	-$5.25M	3.03%	17
2018 Q1	$15.6M	Buy	+164,415	New	+$18.1M	3.09%	16
2017 Q1	–	Sell	-6,500	Closed	-$407K	–	49
2016 Q4	$407K	Sell	6,500 -1,000	-13%	-$61K	0.05%	52
2016 Q3	$473K	Sell	7,500 -175	-2%	-$11.3K	0.05%	53
2016 Q2	$475K	Hold	7,675	–	–	0.05%	53
2016 Q1	$438K	Sell	7,675 -825	-10%	-$46K	0.05%	53
2015 Q4	$504K	Hold	8,500	–	–	0.05%	53
2015 Q3	$462K	Hold	8,500	–	–	0.04%	52
2015 Q2	$571K	Hold	8,500	–	–	0.04%	50
2015 Q1	$498K	Hold	8,500	–	–	0.03%	51
2014 Q4	$556K	Hold	8,500	–	–	0.03%	46
2014 Q3	$491K	Hold	8,500	–	–	0.02%	47
2014 Q2	$480K	Hold	8,500	–	–	0.02%	46
2014 Q1	$437K	Hold	8,500	–	–	0.01%	49
2013 Q4	$449K	Sell	8,500 -859	-9%	-$42.2K	0.01%	47
2013 Q3	$419K	Sell	9,359 -1,104,735	-99%	-$49M	0.01%	47
2013 Q2	$46.1M	Buy	+1,114,094	New	+$48.7M	1.39%	30

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Stralem & Co's ABBV Position: Q2 2020 in Review

Stralem & Co reduced its AbbVie (ABBV) stake by 1.2% in Q2 2020, selling an estimated $44.6K and leaving 41,055 shares worth $4.03M. The position accounts for 2.57% of the portfolio, ranked #23.

Stralem & Co first reported a position in ABBV in Q2 2013 and has held it in 25 quarters since. The position peaked at $46.1M in Q2 2013. 2,412 funds tracked by Wall St. Rank hold ABBV as of Q2 2020.

Stralem & Co held 41,055 shares of AbbVie worth $4.03M as of Q2 2020.
Stralem & Co sold 506 AbbVie shares in Q2 2020, an estimated $44.6K.
AbbVie made up 2.57% of Stralem & Co's portfolio in Q2 2020, its #23 holding.
Stralem & Co first reported a position in AbbVie in Q2 2013 and has held it in 25 quarters since.
Stralem & Co's AbbVie position peaked at $46.1M in Q2 2013.
2,412 funds tracked by Wall St. Rank held AbbVie as of Q2 2020.

Based on Stralem & Co's 13F filing for Q2 2020, filed 20 Jul 2020.